Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 1/2004

01-03-2004

Frequency of extra-colonic tumors in hereditary nonpolyposis colorectal cancer (HNPCC) and familial colorectal cancer (FCC) Brazilian families: An analysis by a Brazilian Hereditary Colorectal Cancer Institutional Registry

Authors: Fáblio Oliveira Ferreira, Claudia Cristina Napoli Ferreira, Benedito Mauro Rossi, Wilson Toshihiko Nakagawa, Samuel Aguilar Jr., Erika Maria Monteiro Santos, Marcelo Leite Vierira Costa, Ademar Lopes

Published in: Familial Cancer | Issue 1/2004

Login to get access
Metadata
Title
Frequency of extra-colonic tumors in hereditary nonpolyposis colorectal cancer (HNPCC) and familial colorectal cancer (FCC) Brazilian families: An analysis by a Brazilian Hereditary Colorectal Cancer Institutional Registry
Authors
Fáblio Oliveira Ferreira
Claudia Cristina Napoli Ferreira
Benedito Mauro Rossi
Wilson Toshihiko Nakagawa
Samuel Aguilar Jr.
Erika Maria Monteiro Santos
Marcelo Leite Vierira Costa
Ademar Lopes
Publication date
01-03-2004
Publisher
Kluwer Academic Publishers
Published in
Familial Cancer / Issue 1/2004
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1023/B:FAME.0000026810.99776.e9

Other articles of this Issue 1/2004

Familial Cancer 1/2004 Go to the issue

OriginalPaper

Familial Cancer 2003 – Research and Practice, Couran Cove, Queensland, Australia, 3–6 September 2003

OriginalPaper

Delivering Information about Cancer Genetics via Letter to Patients at Low and Moderate Risk of Familial Cancer: A Pilot Study in Wales

OriginalPaper

BRCA1 testing with definitive results: a prospective study of psychological distress in a large clinic-based sample

OriginalPaper

BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect

OriginalPaper

Health economics and genetic service development: a familial cancer genetic example

OriginalPaper

The 1100delAT BRCA1 and the 8765delAG BRCA2 Mutations: Occurrence in High-Risk Non-Ashkenazi Jews and Haplotype Comparison of Jewish and Non-Jewish Carriers
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits